Naurex to Present Preclinical and Clinical Data for NRX-1074 and Rapastinel at Upcoming Scientific Meetings

EVANSTON, Ill., May 12, 2015 /PRNewswire/ -- Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the brain and nervous system, today announced that data from clinical and preclinical studies of NRX-1074 and rapastinel (GLYX-13) will be presented at two upcoming scientific conferences.

At the 70^th Annual Scientific Meeting of the Society of Biological Psychiatry (SOBP), held at the Fairmont Royal York Hotel in Toronto, data from the single-dose, Phase 2 clinical trial of NRX-1074 will be presented for the first time. Wen Yu, M.D., senior medical director at Naurex, will present these data in a late-breaking oral presentation at 3 p.m. EDT on Thursday, May 14 in Tudor 8.

Also at the Annual Scientific Meeting of the SOBP, Jeffrey Burgdorf, Ph.D., of the Falk Center for Molecular Therapeutics at Northwestern University will present data from preclinical studies of NRX-1074 in animal models of depression. Dr. Burgdorf's poster presentation will take place at 5 p.m. EDT on Friday, May 15, in the Concert Hall.

At the 34^th Annual Scientific Meeting of the American Pain Society, held at the Palm Springs Convention Center in Palm Springs, Calif., Nayereh Ghoreishi-Haack, senior research technologist at Naurex, will present data from several preclinical studies of rapastinel in pain. Dr. Ghoreishi-Haack's poster presentation will take place at 3:45 p.m. PDT on Thursday, May 14.

About Naurex Inc.
Naurex is a clinical stage biopharmaceutical company developing transformative therapies for challenging disorders of the brain and nervous system. The company has built a platform for discovering drugs that enhance synaptic plasticity, the main process through which nerve cells modify their activity in response to stimuli. Molecules discovered by Naurex achieve this through a novel mechanism that modulates NMDA receptors – rather than shutting them down – resulting in drugs that are both highly effective and well tolerated. Naurex's lead molecule, rapastinel (GLYX-13), has demonstrated rapid, substantial, and sustained reductions in depressive symptoms in multiple Phase 2 clinical studies in major depressive disorder, an area of high unmet need that has seen little innovation in decades. NRX-1074, a next-generation, orally bioavailable drug candidate, is in Phase 2 clinical development in major depressive disorder. Naurex's platform has yielded a rich pipeline of subtype-selective NMDA receptor modulators with the potential to treat a broad set of psychiatric and neurologic disorders. For more information, visit www.naurex.com

Media Contacts:
Canale Communications
Ian Stone
[email protected]
619-849-5388

Naurex Inc.
Ashish Khanna
Vice President, Corporate Development
[email protected]
847-871-0377

SOURCE Naurex Inc.

Related Links

http://www.naurex.com